In summary, this study revealed that EpCAM antibodies were more effective in isolating CTCs from patients with localized prostate cancer, while vimentin antibodies were superior for in metastatic prostate cancer. The gene discussed is EPCAM; the disease is metastatic prostate carcinoma.